<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39356038</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0412</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Acta obstetricia et gynecologica Scandinavica</Title><ISOAbbreviation>Acta Obstet Gynecol Scand</ISOAbbreviation></Journal><ArticleTitle>COVID-19 pandemic impact on gynecologic cancer treatment pathways in a Finnish tertiary center.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/aogs.14981</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">COVID-19 and new guidelines during the pandemic affected the gynecologic cancer treatment pathways, resulting in recorded delays and modifications in the treatment protocols. The aim of this study was to determine the impact of the COVID-19 pandemic in one of the major gynecologic cancer care centers in Finland, Tampere University Hospital.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Our retrospective register study included 909 patients that were new gynecologic cancer cases (uterine, cervical, vulvar, vaginal, or ovarian) referred to the Tampere University Hospital Gynecologic Oncology Outpatient Clinic between March 17th, 2018, and March 15th, 2022. The patients were divided into two separate groups depending on their time of referral: time before COVID (March 17th, 2018, to March 15th, 2020), and during COVID (March 16th, 2020, to March 15th, 2022). These groups were compared in terms of patient characteristics, different cancer types and stages, symptoms, and treatment methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the COVID-19 pandemic, patients generally suffered from cancer symptoms longer (p &lt; 0.003) and were more likely to be overweight (p = 0.035). The improved multidisciplinary team meeting gave the patients a faster route to their first intervention during COVID (p &lt; 0.05). An insignificant shift toward nonsurgical first interventions and non-curative intent was seen during COVID, but the multidisciplinary team treatment plans were mostly implemented accordingly on both eras. No decrease was seen in the number of new gynecologic cancer cases, and the one-year overall survival remained the same in both groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, the COVID-19 pandemic did not significantly alter treatment pathways in gynecologic cancer care at Tampere University Hospital. The number of new patients and given treatments remained relatively stable. During COVID, access from referral to cancer treatment was significantly accelerated, which is likely confounded by changes to the multidisciplinary team protocol made in early 2021.</AbstractText><CopyrightInformation>© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley &amp; Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pikkujämsä</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0000-3055-5240</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luukkaala</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Reita H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6907-1147</Identifier><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louvanto</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1172-363X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Sigrid Juséliuksen Säätiö</Agency><Country /></Grant><Grant><Agency>Research Counsil of Finland</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Obstet Gynecol Scand</MedlineTA><NlmUniqueID>0370343</NlmUniqueID><ISSNLinking>0001-6349</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">delay</Keyword><Keyword MajorTopicYN="N">gynecologic cancer</Keyword><Keyword MajorTopicYN="N">multidiscipline team meeting</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356038</ArticleId><ArticleId IdType="doi">10.1111/aogs.14981</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. COVID‐19: vulnerable and high risk groups. World Health Organization [Internet]. 2020;1‐5. Accessed December 1, 2023. https://www.who.int/westernpacific/emergencies/covid‐19/information/high‐risk‐groups</Citation></Reference><Reference><Citation>World Health Organization. Archived: WHO Timeline–COVID‐19. 2020.</Citation></Reference><Reference><Citation>Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID‐19 government response tracker). Nat Hum Behav. 2021;5:529‐538.</Citation></Reference><Reference><Citation>Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non‐pharmaceutical interventions on COVID‐19 in Europe. Nature. 2020;584:257‐261.</Citation></Reference><Reference><Citation>Liu Y, Yu Q, Wen H, et al. What matters: non‐pharmaceutical interventions for COVID‐19 in Europe. Antimicrob Resist Infect Control. 2022;11:3.</Citation></Reference><Reference><Citation>Tiirinki H, Tynkkynen LK, Sovala M, et al. COVID‐19 pandemic in Finland—preliminary analysis on health system response and economic consequences. Health Policy Technol. 2020;9:649‐662.</Citation></Reference><Reference><Citation>Paajanen J, Mäkinen LK, Suikkila A, et al. Isolation precautions cause minor delays in diagnostics and treatment of non‐COVID patients. Infect Prev Pract. 2021;3:100178.</Citation></Reference><Reference><Citation>Johansson ALV, Larønningen S, Skovlund CW, et al. The impact of the COVID‐19 pandemic on cancer diagnosis based on pathology notifications: a comparison across the Nordic countries during 2020. Int J Cancer. 2022;151:381‐395.</Citation></Reference><Reference><Citation>Colombo I, Zaccarelli E, Del Grande M, et al. ESMO management and treatment adapted recommendations in the COVID‐19 era: Gynaecological malignancies. ESMO Open. 2020;5:e000827.</Citation></Reference><Reference><Citation>Uwins C, Bhandoria GP, Shylasree TS, et al. COVID‐19 and gynecological cancer: a review of the published guidelines. Int J Gynecol Cancer. 2020;30:1424‐1433.</Citation></Reference><Reference><Citation>Akladios C, Azais H, Ballester M, et al. Recommendations for the surgical management of gynecological cancers during the COVID‐19 pandemic–FRANCOGYN group for the CNGOF. J Gynecol Obstet Hum Reprod. 2020;49:101729.</Citation></Reference><Reference><Citation>Nikolopoulos M, Maheshwari MK, Doumouchtsis SK. Impact of COVID‐19 in gynaecological oncology care: a systematic rapid review. Arch Gynecol Obstet. 2022;305:555‐565.</Citation></Reference><Reference><Citation>Alkatout I, Biebl M, Momenimovahed Z, et al. Has COVID‐19 affected cancer screening programs? A Systematic Review Front Oncol. 2021;11:675038.</Citation></Reference><Reference><Citation>Leibold A, Papatla K, Zeligs KP, Blank SV. COVID‐19 and gynecologic oncology: what have we learned? Curr Treat Options in Oncol. 2021;22:117.</Citation></Reference><Reference><Citation>Uwins C, Bhandoria G. COVID‐19 pandemic impact on gynaecological cancers: a perspective. Br J Surg. 2020;107:e265.</Citation></Reference><Reference><Citation>Leung E, Pervaiz Z, Lowe‐Zinola J, et al. Maintaining surgical care delivery during the COVID‐19 pandemic: a comparative cohort study at a tertiary gynecological cancer centre. Gynecol Oncol. 2021;160:649‐654.</Citation></Reference><Reference><Citation>Antunes D, Mendonça L, Melo Â, Gonçalves S, Nogueira Martins F, Nogueira Martins N. Impact of the COVID‐19 pandemic on diagnosis and Management of Gynecological Cancer: a single‐center analysis. Medicina (B Aires). 2022;58:1862.</Citation></Reference><Reference><Citation>Algera MD, van Driel WJ, Slangen BFM, et al. Impact of the COVID‐19‐pandemic on patients with gynecological malignancies undergoing surgery: a Dutch population‐based study using data from the ‘Dutch gynecological oncology audit’. Gynecol Oncol. 2022;165:330‐338.</Citation></Reference><Reference><Citation>Frey MK, Fowlkes RK, Badiner NM, et al. Gynecologic oncology care during the COVID‐19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020;159:470‐475.</Citation></Reference><Reference><Citation>Bruce SF, Huysman B, Bharucha J, et al. Impact of the COVID‐19 pandemic on referral to and delivery of gynecologic oncology care. Gynecol Oncol Rep. 2022;39:100928.</Citation></Reference><Reference><Citation>Ritchie H, Mathieu E, Rodés‐Guirao L, et al. Coronavirus Pandemic (COVID‐19). 2020. https://ourworldindata.org/coronavirus</Citation></Reference><Reference><Citation>Akter T, Zeba Z, Hosen I, Al‐Mamun F, Mamun MA. Impact of the COVID‐19 pandemic on BMI: its changes in relation to socio‐demographic and physical activity patterns based on a short period. PLoS One. 2022;17:e0266024.</Citation></Reference><Reference><Citation>Dicken SJ, Mitchell JJ, Le Vay JN, et al. Impact of covid‐19 pandemic on weight and bmi among UK adults: a longitudinal analysis of data from the hebeco study. Nutrients. 2021;13:2911.</Citation></Reference><Reference><Citation>Sharma H. Statistical significance or clinical significance? A researcher's dilemma for appropriate interpretation of research results. Saudi J Anaesth. 2021;15:431‐434.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>